Recombinant Human BTN3A2 Protein, CF
View Webinar
Recombinant Human BTN3A2 Protein, CF Summary
Product Specifications
Gln30-Trp248, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9514-BT
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 200 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant Human BTN3A2 (Catalog # 9514-BT) enhances anti-CD3 antibody induced IFN-gamma secretion by mouse CD3+T cells. The ED50 for this effect is 0.5-2.5 μg/mL.
Reconstitution Calculator
Background: BTN3A2
BTN3A2 (Butyrophilin subfamily 3 member A2; also BTF3 and BT3.2) is a 36 kDa (predicted) glycoprotein, member of the BTN family, Ig Superfamily of molecules. It is postulated to be expressed on immune-related cells, as it has a structural similarity to MHC and CD80/CD86 molecules. Mature human BTN3A2 is a 305 amino acid (aa) type I transmembrane protein. It contains a 219 aa extracellular region with one V-type Ig-like domain and a 65 aa cytoplasmic tail. The cytoplasmic region undergoes phosphorylation on two serines. There are three potential splice forms. A rodent counterpart to BTN3A2 has not been reported. BTN3A2 mRNA over‑expression was associated with a good prognosis in relation to disease-free and overall survival in a cohort of 55 epithelial ovarian cancer (EOC) patients (1). Another study in a larger cohort of 199 high-grade EOC patients further confirmed that the protein expression of BTN3A2 in ovarian cancer tissues is positively correlated with the intraepithelial infiltration of CD4+ and CD8+ T cells (2), suggesting that BTN3A2 was a co-stimulatory molecule to modulate the infiltration of immune cells and thus the anti-cancer immunity. In consistent with previous publications, our in-house studies on BTN3A2 showed that BTN3A2 co-stimulated anti‑CD3 induced IFN-gamma secretion on CD3+ cells.
- LePage C, et al. Cancer Epidemiol Biomarkers Prev (2008) 17:913.
- LePage C, et al. PLoSOne (2012) 7:e38541.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human BTN3A2 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human BTN3A2 Protein, CF and earn rewards!
Have you used Recombinant Human BTN3A2 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
